Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-cash Items (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Non-cash Items for 7 consecutive years, with $12.6 million as the latest value for Q2 2025.

  • Quarterly Non-cash Items rose 969.92% to $12.6 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $12.6 million through Jun 2025, up 969.92% year-over-year, with the annual reading at $8.0 million for FY2024, 9.02% down from the prior year.
  • Non-cash Items hit $12.6 million in Q2 2025 for BridgeBio Pharma, up from $994768.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $114.3 million in Q1 2021 to a low of $314218.0 in Q1 2024.
  • Historically, Non-cash Items has averaged $15.4 million across 5 years, with a median of $3.9 million in 2022.
  • Biggest five-year swings in Non-cash Items: skyrocketed 40004.21% in 2021 and later tumbled 99.38% in 2024.
  • Year by year, Non-cash Items stood at $8.0 million in 2021, then plummeted by 82.06% to $1.4 million in 2022, then skyrocketed by 748.28% to $12.1 million in 2023, then plummeted by 33.95% to $8.0 million in 2024, then skyrocketed by 57.8% to $12.6 million in 2025.
  • Business Quant data shows Non-cash Items for BBIO at $12.6 million in Q2 2025, $994768.0 in Q1 2025, and $8.0 million in Q4 2024.